Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:42:35.158Z.
Calculation as of: 2026-10-06T15:42:35.158Z.
Quote observation: 2026-10-06T15:40:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1439c3a9e54fb1f97ae208c5489c534aa692153c8f3b45d8dac24981f451ae3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$20.99M
PS Ratio
N/A
TTM Avg
252.77
3Y Avg
5169.56
5Y Avg
5169.56
Market Cap
$24.74M
PS Ratio
N/A
TTM Avg
587.77
3Y Avg
330.78
5Y Avg
314.70
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | $22.32M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.65M | 0.39 | 0.46 | 0.28 | 0.24 |
| Modular Medical, Inc. (MODD)vs › | $21.03M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.99M | N/A | 252.77 | 5169.56 | 5169.56 |
| Kyntra Bio, Inc. (KYNB)vs › | $24.09M | 5.22 | 4.70 | 1.77 | 4.39 |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | N/A | 587.77 | 330.78 | 314.70 |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.96M | N/A | 8459.04 | 2873.24 | 1783.28 |
| P3 Health Partners Inc. (PIII)vs › | $19.72M | 0.01 | 0.02 | 0.04 | 0.14 |
| Actuate Therapeutics Inc (ACTU)vs › | $19.64M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $19.14M | N/A | 15.99 | 112.90 | 112.90 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
